clinical trial · NCT04686136
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
AbbVie·phase3·completed·n = 596
Episodic MigraineChronic MigraineAtogepant 60 mg
brief summary
This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
started
Feb 19, 2021
primary completion
Oct 20, 2025
completion
Oct 20, 2025
last updated
Dec 18, 2025
official title
A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol